Member Info for Timster

Someone knows something

Can't believe there's a list of people who don't like you :)

98p

I've noticed a lot of 3 and 7 share buys going through, is that you're chomp?

He's still going though, him and his mate are very 'concerned'investors

Myles has educated the twunts

Obviously I did have a chomp.

But yeah pl75 a meeting end of Feb is not that interesting unless you know the background

If you were a professional investor/strategist who has a good rumage through a days RNS's would you have just skipped over today's having no knowledge of Avacta?

We all know what it means, or we hope we do as we've studied Alan and his science in minute detail.

This science day is almost certainly to inform the world avacta are bankrupt and the death spiral is complete...

Key speech

Who will the KOL's be, chief investigator from Marsden would be a good bet. Bet he's bought a few shares ....

What dyou go and put up the W signal for?

And this too
The Company will update the Market on progress in this study in early January 2023, in advance of the Science Day.

Any thoughts as to what big Al's calender shows for an early Jan date :)

Interesting read
https://www.aptitudehealth.com/oncology-news/value-of-kol-oncology-hematology/

There’s no doubt that KOLs guide decision-making within the hematology/oncology community. Clinicians, patients, and caregivers rely on these experts to guide their treatment decisions. KOLs can also boost participation in clinical trials and ensure their success, but not all of these thought leaders offer your organization equal expertise.

Alan says positive phase 1a proves the platform and would be a major inflection point.

What does proving the pre|CISION platform mean to you?

Here we go, these are the objectives, and we know biopsies are highly likely, make up your own mind.

Primary Objectives:
To evaluate the safety and tolerability of AVA6000.
To determine the maximumtolerated dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) for the dose expansion phase.

Secondary Objectives:
To characterise the pharmacokinetics (PK) in plasma, urine and tumour of AVA6000, of the preCISION and of active metabolites (doxorubicin and leaving group, ) when given as monotherapy, after a single dose and after multiple dosing. doxorubicinol
To evaluate the initial antitumour activity of AVA6000 according to RECIST.1.1 criteria (overall response rate [ORR], duration of response [ DoR ], disease control rate [DCR] progression free survival [PFS ] and overall survival

Are they there to say "well done Avacta, it doesn't work though"

Gives a target for shorters and traders though SP will be all over the place.

Don't forget all the other news items on the horizon though....

At least it's an RNS I suppose.

Could have done with a bit more detail